top of page
OSU-FNDR Conference Banner.png

Foundation for Neglected Disease Research and The Ohio State University's Global Gateways (India) are organizing an International Conference on Recent Advancements in TB and HIV Research. The speakers are TB and HIV researchers and clinicians from The Ohio State University, Indian academia, public health institutions, and industry. The conference gives an opportunity to researchers, clinicians, and stakeholders to network and discuss recent advancements in TB and HIV research. 

​


Date: January 11, 2023
Time: 8 AM to 6 PM
Venue: Hotel Shangri-La, Bengaluru


 

Morning tea starts at 8 AM at Krishna Hall, Shangri-La. 

Buffet lunch and refreshments will be provided. 

The conference is free-of-charge for the attendees. However, prior registration is mandatory. 

AGENDA

8 AM Tea

​

9 AM Welcome

​

Welcome Address by Co-Chairs

Dr Shridhar Narayanan, Co-founder and Chief Executive Officer, Foundation for Neglected Disease Research

Dr Shu Hua Wang, Professor, The Ohio State University and Director, OSU Global One Health initiative (GOHi)

​

9.10 AM Opening Remarks

​

Government of India's strategy and commitment to combat TB

Dr Padmapriyadarsini C, Director, ICMR-National Institute for Research in Tuberculosis

​

9.30 AM Session 1

​

TB & HIV - clinical updates from the Indian context

Dr George D'Souza, Dean, St. John's Medical College

​

New oral regimens for drug susceptible and drug resistant TB

Zoonotic TB - A One Health Approach to elimination of TB

Dr Shu Hua Wang, Professor, The Ohio State University and Director, OSU Global One Health initiative (GOHi)

​

Pediatric TB

Dr Ira Shah, Professor and Head, Pediatric Infectious Diseases, B.J. Wadia Hospital for Children

​

11 AM Tea & Networking

​

11.30 AM Session 2

​

TB control and prevention in a hospital setting

Dr Rajesh Deshmukh, Public Health Specialist, TB, Division of Global HIV and TB, CDC 

​

Biosensors: Challenges in translating concepts to products

Dr Chandrasekhar Nair, Co-founder & Chief Technology Officer of Molbio Diagnostics

​

Brd4 co-modulates host-angiogenesis and lipophagy and exacerbates Mycobacterium tuberculosis infection

Dr Balaji K N, Professor, Indian Institute of Science

​

1 PM Lunch & Networking

​

2 PM Session 3

​

Innate Immune responses to BCG vaccination

Dr Namal Liyanage, Assistant Professor, The Ohio State University

​

Investigating novel Toxin/Anti-Toxin systems, the molecular breaks in Mycobacterium tuberculosis

Dr Krishan Gopal, Principal Scientist, CSIR-IMTECH

​

Macrophage p-glycoprotein: a new target for TB therapy

Dr Murugesan Rajaram, Associate Professor, The Ohio State University

​

3.30 PM Tea & Networking

​

4 PM Session 4

​

Next generation TB vaccines that elicit mucosal immunity

Dr Purnima Dubey, Associate Professor, The Ohio State University

​

Macrophage heterogeneity promotes drug tolerance in Mycobacterium tuberculosis

Dr Amit Singh, Associate Professor, Indian Institute of Science

​

Current TB Drug Pipeline and Discovery of TBA-7371

Dr R K Shandil, Co-founder & Chief Scientific Officer, Foundation for Neglected Disease Research

​

5.30 PM Closing Remarks

​

bottom of page